Trellis Bioscience has closed a $9m Series C funding round to support the completion of its ongoing Phase II clinical trial evaluating calpurbatug (TRL1068), a monoclonal antibody candidate for chronic prosthetic joint infections (PJI). The ongoing trial is b…
Trellis Bioscience has closed a $9m Series C funding round to support the completion of its ongoing Phase II clinical trial evaluating calpurbatug (TRL1068), a monoclonal antibody candidate for chron…